5.52
-0.09 (-1.60%)
| Previous Close | 5.61 |
| Open | 5.61 |
| Volume | 966,375 |
| Avg. Volume (3M) | 1,757,424 |
| Market Cap | 1,767,564,800 |
| Price / Book | 9.10 |
| 52 Weeks Range |
| Operating Margin (TTM) | -436.94% |
| Diluted EPS (TTM) | -0.150 |
| Quarterly Revenue Growth (YOY) | 49.70% |
| Current Ratio (MRQ) | 19.05 |
| Operating Cash Flow (TTM) | -43.24 M |
| Levered Free Cash Flow (TTM) | -29.52 M |
| Return on Assets (TTM) | -24.19% |
| Return on Equity (TTM) | -39.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | CLARITY PH FPO [CU6] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.63 |
|
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology. It operates as a single segment, which is Development of Radiopharmaceuticals. Geographically, it operates in Australia and the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 27.93% |
| % Held by Institutions | 12.04% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |